Literature DB >> 25977339

Drug combination studies and their synergy quantification using the Chou-Talalay method--letter.

John C Ashton1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25977339     DOI： 10.1158/0008-5472.CAN-14-3763

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  50 in total

1.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Authors:  Jia Wang; Peng Cheng; Marat S Pavlyukov; Hai Yu; Zhuo Zhang; Sung-Hak Kim; Mutsuko Minata; Ahmed Mohyeldin; Wanfu Xie; Dongquan Chen; Violaine Goidts; Brendan Frett; Wenhao Hu; Hongyu Li; Yong Jae Shin; Yeri Lee; Do-Hyun Nam; Harley I Kornblum; Maode Wang; Ichiro Nakano
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

2.  Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.

Authors:  Raghavendra Gowda; Gregory Kardos; Arati Sharma; Sanjay Singh; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2016-12-21       Impact factor: 6.261

3.  Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines.

Authors:  Yuqian Liu; Ruochen Zang; Feifei Li; Chuanqin Shi; Jianchun Zhao; Lili Zhong; Xin Wang; Jinbo Yang; Wenbao Li
Journal:  Invest New Drugs       Date:  2019-12-04       Impact factor: 3.850

4.  JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Authors:  Sara Yumeen; Fatima N Mirza; Julia M Lewis; Amber Loren O King; Sa Rang Kim; Kacie R Carlson; Sheila R Umlauf; Yulia V Surovtseva; Francine M Foss; Michael Girardi
Journal:  Blood Adv       Date:  2020-05-26

5.  A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer.

Authors:  Xiaoli Liu; Wei Wang; Yanping Yin; Ming Li; Hong Li; Hang Xiang; Ao Xu; Xiaodong Mei; Bo Hong; Wenchu Lin
Journal:  Invest New Drugs       Date:  2019-03-02       Impact factor: 3.850

6.  Quantifying Drug Combination Synergy along Potency and Efficacy Axes.

Authors:  Christian T Meyer; David J Wooten; B Bishal Paudel; Joshua Bauer; Keisha N Hardeman; David Westover; Christine M Lovly; Leonard A Harris; Darren R Tyson; Vito Quaranta
Journal:  Cell Syst       Date:  2019-02-20       Impact factor: 10.304

7.  Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.

Authors:  Juhong Jiang; Yuanzhi Lu; Zhi Li; Liping Li; Daoli Niu; Wenwei Xu; Jing Liu; Lin Fu; Ziqing Zhou; Yingying Gu; Fen Xia
Journal:  Invest New Drugs       Date:  2017-01-23       Impact factor: 3.850

8.  Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.

Authors:  Meng Lou; Qian Liu; Guoping Ren; Jiling Zeng; Xueping Xiang; Yongfeng Ding; Qinghui Lin; Tingting Zhong; Xia Liu; Lijun Zhu; Hongyan Qi; Jing Shen; Haoran Li; Jimin Shao
Journal:  J Biol Chem       Date:  2017-04-14       Impact factor: 5.157

9.  Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors.

Authors:  Suhui Yang; Andrea Shergalis; Dan Lu; Anahita Kyani; Ziwei Liu; Mats Ljungman; Nouri Neamati
Journal:  J Med Chem       Date:  2019-04-02       Impact factor: 7.446

10.  Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.

Authors:  Yanting Zhang; Rena G Lapidus; Peiyan Liu; Eun Yong Choi; Samusi Adediran; Arif Hussain; Xinghuan Wang; Xuefeng Liu; Han C Dan
Journal:  Mol Cancer Ther       Date:  2016-04-08       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.